Illumina recently announced the TruSight Tumor 170, a next-generation sequencing solution that detects 170 genes, marking the transformation of tumor profiling from a range of single-gene detection to multi-gene detection, providing a more comprehensive view of the tumor genome. view.
TruSight Tumor 170 provides an integrated, DNA- and RNA-based workflow that targets cancer-related gene mutations, including mutations and microdeletions, gene amplification, gene fusion, and splice variants. Research experiments can be performed on the NextSeq device in the laboratory through optimized bioinformatics tools and automation options. TruSight Tumor 170 supports micronucleic acids obtained from formalin fixed paraffin-embedded (FFPE) samples to improve the efficiency of biomarkers.
“With a wider range of genetic content, we can advance cancer research by assessing more genes and identifying structural changes that are important targets in the development of new therapies,†says pathologist Anthony Magliocco. “We hope to improve clinical cancer research by streamlining the detection of solid tumors. Because the TruSight Tumor 170 uses a flexible enrichment approach, the technology may be used as a platform in many other areas beyond solid tumor profiling.â€
"This new experimental analysis will help stimulate the potential of precision oncology," said Dr. John Leite, vice president of oncology at Illumina. “By integrating DNA and RNA into a single program, clinical researchers can accelerate the most comprehensive and relevant variability information from cancer samples. In the future, we hope that TruSight Tumor 170 will become a standard analytical method, regardless of the fixed gene Set or customized gene sets are able to perform the best analysis and evaluation of the organization.
“We are committed to continuing to provide tools that contribute to the shared vision of personalized oncology,†said Illumina President and CEO Francis de Souza. “We believe that the introduction of the TruSight Tumor 170 will contribute to the development of research, which will definitely have a positive impact on cancer patients.â€
Analog Intercom System,Analog System 4 Wire Video Doorbell,Video 4 Wire Intercom System,4 Wire Doorbell,4 Wire Doorbell Made In China
Zhuhai Mingke Electronics Technology Co., Ltd , https://www.zhmkdz-electronics.com